Search Articles
Search results
Displaying 1 - 20 of 103
![CAR T cell therapy](/sites/default/files/styles/square_004000_160x160/public/images/ff/car-t-cells-mixed.jpg?f=ca39b472&itok=WJFh-DW6)
Cancer,
Science & Research
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new CAR T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
February 16, 2024
|
4 min read
![immunotherapy kids blog](/sites/default/files/styles/square_004000_160x160/public/banner-images/6a/immunotherapy-kids-blog.jpg?f=81f02e76&itok=GA18uDZa)
Healthy Lifestyle
Pros and cons of allergy immunotherapy for children
Allergy immunotherapy for children can provide symptom relief and reduce the need for medication. Here’s what you need to know.
February 14, 2024
|
4 min read
![Ribas lab.](/sites/default/files/styles/square_004000_160x160/public/images/6f/img-7655_0.jpeg?f=1e2d750c&itok=7Is_gbE2)
Cancer,
Science & Research
Study reveals hidden immune defense against cancer
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found certain immune cells can still fight cancer even when the cancer cells lack an important protein that the immune system relies on to help track down cancer cells.
November 28, 2023
|
3 min read
![Dr. Bryan Burt](/sites/default/files/styles/square_004000_160x160/public/images/e4/bryan-burt-rev.jpg?f=48bac35a&itok=E3J6Y6QI)
Cancer,
Science & Research
Surgeon and thoracic surgical oncologist Dr. Bryan Burt named chief of thoracic surgery at UCLA Health
Burt also leads an NIH-funded research laboratory focused on understanding mechanisms of response and resistance to immunotherapy, and improving intraoperative margin assessment in thoracic malignancies.
November 28, 2023
|
2 min read
![CAR T-cell Therapy](/sites/default/files/styles/square_004000_160x160/public/images/T-cells-cancer-vertical.jpg?h=9c86ceb9&itok=nEpz1Rzx)
Cancer,
Science & Research
Scientists engineer potent immune cells for ‘off-the-shelf’ cancer immunotherapy
UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.
November 8, 2023
|
3 min read
![Nanocapsule](/sites/default/files/styles/square_004000_160x160/public/images/a4/science-horizontal_0.jpg?f=bb1e0233&itok=zbHDfkqs)
Cancer,
Science & Research
Drug-filled nanocapsule helps make immunotherapy more effective in mice
UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.
October 11, 2023
|
3 min read
![Cancer Cells](/sites/default/files/styles/square_004000_160x160/public/images/80/shutterstock-2033260514.jpg?f=b9d18637&itok=SYfLUpJV)
Cancer,
Science & Research
Scientists develop roadmap to create new treatment strategies for ovarian cancer
UCLA researchers have created a roadmap looking at different ways to use the immune system to fight ovarian cancer, which could ultimately lead to the development of more effective immunotherapeutic strategies to better treat the often-lethal cancer.
October 11, 2023
|
3 min read
![Ameya Champhekar](/sites/default/files/styles/square_004000_160x160/public/images/87/2023-10-05-uclah-jccc-champhekar-005-cropped-2_0.jpg?f=39c45982&itok=1_qXPq1B)
Cancer,
Science & Research
Scientists identify new pathway activated by interferon-gamma that leads to tumor cell death
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new role for a protein called extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that can trigger cells to self-destruct.
October 9, 2023
|
3 min read
![Edward Garon](/sites/default/files/styles/square_004000_160x160/public/images/46/edward-garon-md-phd-cropped.jpg?f=74506653&itok=jgwk4SYm)
Cancer,
Science & Research
Dr. Edward Garon receives $3.5 million from NIH to personalize immunotherapy based on individual patients’ mutations
Dr. Edward Garon was awarded two grants totaling over $3.5 million from the National Institutes of Health to help improve outcomes for patients with early and advanced stages of non-small cell lung cancer.
September 27, 2023
|
2 min read
![Melissa Lechner, MD](/sites/default/files/styles/square_004000_160x160/public/images/45/melissalechner-crop.jpg?f=95d4c682&itok=UxODccAE)
Cancer,
Science & Research
Dr. Melissa Lechner receives grant from Doris Duke Foundation
Dr. Melissa Lechner has received a $495,000 grant from the Doris Duke Foundation to help develop ways to minimize harmful immune reactions some people diagnosed with cancer experience when undergoing immunotherapy treatment.
September 8, 2023
|
2 min read
![glioblastoma cells](/sites/default/files/styles/square_004000_160x160/public/images/23/perivascularcuffing-01_0.jpg?f=0e53911d&itok=VxyruQZD)
Cancer,
Science & Research
Study could help explain why certain brain tumors don’t respond well to immunotherapy
A study led by researchers at UCLA sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.
September 1, 2023
|
5 min read
![T cells attacking cancer cells](/sites/default/files/styles/square_004000_160x160/public/images/ef/istock-1055267942-1.jpg?f=3d1a36f2&itok=UXd27hZV)
Cancer,
Science & Research
Immunotherapy drug combo helps extend the lives of patients with metastatic melanoma
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with a deadly type of melanoma that is resistant to immunotherapy drugs known as PD-1 inhibitors.
August 17, 2023
|
4 min read
![Christine Mona, PhD](/sites/default/files/styles/square_004000_160x160/public/images/75/christinemona_0.jpg?f=02228e3d&itok=hbLch5Mk)
Cancer,
Science & Research
Researchers awarded $2 million grant from National Cancer Institute
Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $2 million grant from the National Cancer Institute to design better combination therapies that target the immune system to treat metastatic castration-resistant prostate cancer, which continues to spread even when testosterone levels are significantly reduced.
July 11, 2023
|
2 min read
![immunotherapy](/sites/default/files/styles/square_004000_160x160/public/images/71/istock-1055267942.jpg?f=3d1a36f2&itok=L9dAg5yd)
Cancer,
Science & Research
UCLA researchers uncover potential biomarkers of positive response to immunotherapy
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
June 26, 2023
|
4 min read
![CAR T-cell Therapy](/sites/default/files/styles/square_004000_160x160/public/images/T-cells-cancer-vertical.jpg?h=9c86ceb9&itok=nEpz1Rzx)
Cancer,
Science & Research
UCLA researchers engineer resistance-proof CAR T cells
In a Phase 1 clinical trial, the ‘bispecific’ therapy showed safe, long-lasting results.
May 22, 2023
|
4 min read
![UCLA cancer reseachers Drs. Melissa Lechner and Maureen Su](/sites/default/files/styles/square_004000_160x160/public/images/e7/maureen-su-melissa-lechner-1.jpg?f=0ec2e800&itok=qEtoQTIq)
Cancer,
Science & Research
Researchers identify potential new strategy to prevent side effects from immunotherapy
A UCLA study lsuggests that IL-21, a soluble molecule involved in activating the immune system, can be a potential therapeutic target to help reduce endocrine autoimmune side effects caused by checkpoint inhibitor cancer therapy.
May 17, 2023
|
3 min read
![Cells 3D illustration, early stage embryo scientific concept Stem cell research](/sites/default/files/styles/square_004000_160x160/public/images/Cells-3D-Illustration.jpg?h=d39dbc10&f=c602f679&itok=XkOZsrUT)
Cancer,
Science & Research
In a ‘rapid autopsy’ study, UCLA researchers identify lethal molecular alterations after present-day therapies fail patients with metastatic melanoma
In a new UCLA translational study, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies. Results are published online ahead of print in Nature Medicine.
April 27, 2023
|
6 min read
![Patient consults with health care practitioner](/sites/default/files/styles/square_004000_160x160/public/images/03/istock-1384528178.jpg?f=b3ee5647&itok=wxjceAPS)
Cancer,
Science & Research
Prior treatments influence immunotherapy response in advanced melanoma
Researchers led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.
April 10, 2023
|
4 min read
![Photo of awardees](/sites/default/files/styles/square_004000_160x160/public/images/3d/cirm-disc0-grant-announcement-website.png?f=3515ccd4&itok=lhV2jAJt)
Cancer,
News about UCLA Health
UCLA scientists receive $5.7 million in CIRM grants to advance stem cell-based technologies for treating cancer, infertility, intellectual disability syndromes and cystic fibrosis
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received more than $5.7 million in grants to advance stem cell-based technologies for treating cancer, infertility, intellectual disability syndromes and cystic fibrosis.
March 28, 2023
|
4 min read
![XX chromosomes](/sites/default/files/styles/square_004000_160x160/public/images/99/xx-chromosomes-istock-700x466.jpg?f=1f42e24c&itok=OLZ_oQYj)
Science & Research
An extra X chromosome-linked gene may explain decreased viral infection severity in females
It has long been known that viral infections can be more severe in males than females, but the question as to why has remained a mystery – until possibly now. The key may lie in an epigenetic regulator that boosts the activity of specialized anti-viral immune cells known as natural killer (NK) cells. A collaborative team of UCLA researchers have found that female mouse and human NK cells have an extra copy of an X chromosome-linked gene called UTX. UTX acts as an epigenetic regulator to boost NK cell anti-viral function, while repressing NK cell numbers.
March 20, 2023
|
3 min read